Variant of Concern 202012/01Technical briefing 6 This briefing provides an update on previous briefings up to 1 February 2021 Summary There are 4 variants of concern, designated: • VOC 202012/01 (B.1.1.7), first detected in Kent England is predominant in all regions and is circulating in multiple countries• VOC 202102/02 (B.1.1.7 cluster with E484K mutation), first detected in South West […]
Category Archives: Diagnostics
Variant of Concern 202012/01Technical briefing 5 This briefing provides an update on the briefing of 14 January 2021 Summary SGTF detections indicate VOC202012/01 continues to predominate across all regions. S gene target failure remains a well correlated proxy measure of VOC 202012/01. An assessment of severity of disease has been conducted by NERVTAG. A limited […]
Variant of Concern 202012/01 Technical briefing 4 This briefing provides an update on the briefing of 8 January 2021 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, […]
The world is in midst of the COVID-19 pandemic.The SARS-CoV-2 lineage B.1.1.28 has been evolving in Brazil since February 2020. A new lineage, named P.1 (B.1.1.28.1), contains convergent mutations in the spike (S) protein, including several receptor binding domain (spike RBD) mutations E484K, K417T, and N501Y. Spike Mutation in SARS-COV-2 (2019nCOV) Brazilian variant P.1 lineage […]
Variant of Concern 202012/01Technical briefing 3 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, month, and number. Following risk assessment with the relevant expert committee, they may […]
The world is in midst of the COVID-19 pandemic. Recently a new SARS-CoV-2 (2019nCOV) lineage (501Y.V2,, B.1.351), characterised by eight lineage-defining mutations in the spike protein (excluding D614G mutation), including three at important residues in the receptor-binding domain (K417N, E484K and N501Y), represents increased transmissibility. This lineage emerged in South Africa and spread rapidly, becoming […]
About SARS-CoV-2 (2019nCoV, novel Coronavirus) Spike protein, S1 Protein, Spike S1-NTD, Spike S1-CTD, Spike-RBD and Spike trimer protein. 1. SARS-CoV-2 (2019nCoV) Spike protein: SARS-CoV-2, a newly emerged pathogen spreading worldwide. The transmembrane spike (S) glycoprotein of SARS-CoV-2 that forms homotrimers protruding from the viral surface is known to mediate coronavirus entry into host cells. It has been […]
Figure. Validation of SARS-CoV-2 (2019nCoV) codon optimized (CO) Spike expression in HEK293 cell line by GeneMedi’s adenoviral vector (GMV-V-2019nCoV-053, GMV-V-2019nCoV-047) and lentiviral vector (GMV-V-2019nCoV-051) with Immunofluorescence (left) and Western Blot (right) by FLAG antibody. Collection of COVID-19 landscape knowledge base Viral vector-based vaccine; DNA-based vaccine; RNA based vaccine – A landscape for vaccine technology against infectious disease, COVID-19 and tumor. COVID-19 landscape […]
About Pre-made gene ORF plasmids for 2019 nCoV (SARS2 coronavirus, COVID-19) COVID-19, a novel pathogenic coronavirus (2019-nCoV or SARS-CoV2) induced disease, emerged in China and spread globally rapidly. GeneMedi offers pre-made gene ORF plasmids for 2019 nCoV (SARS2 coronavirus, COVID-19) as shown below: N protein(Nucleocapsid), S protein(Spike, full lenth), S1 protein(Spike), S protein RBDS protein […]
PSV validated Data Poster Download Protocol Download COVID-19 News and announcements collection on the new mutant variants of the SARS-CoV-2 (2019nCoV) virus – PHE investigating a novel variant of COVID-19– Rapid evaluation confirms lateral flow devices effective in detecting new COVID-19 variant– Confirmed cases of COVID-19 variant from South Africa identified in UK– Statement from […]
